Satakarni Makkapati, CEO, Aurobindo Biosimilars
Hyderabad Aurobindo Pharma’s plans to tap the potential for biosimilars in the European market are all set to materialise in the current financial year.
According to Satakarni Makkapati, CEO of Aurobindo Biosimilars, Vaccines, and Peptide Businesses at Aurobindo Pharma, the company expects revenue from the Biosimilars segment vertical in Europe to start from the third/fourth quarter of the current financial year.
The Hyderabad-based company had already obtained necessary regulatory approvals from the European Union and commenced manufacturing for commercial supplies, and had already supplied some drugs to the UK.
Initial focus on launch quantities and supply chain
“In the first six months leading up to March (next year) will essentially be meeting the launch quantities, enabling our commercial operations teams and our partners to park the launch quantities in the markets they desire to,” the CEO said in response to a query.
The revenue, however, could be a `very small single-digit commercial revenue’ as the present focus of Aurobindo is to ensure adequate supplies. The company is stabilising its QP testing services in Europe through CRO partners and through its setup in Malta, which will function seamlessly in releasing and testing biosimilars.
Commercialisation split between direct and partner-led markets
While in the markets where Aurobindo is directly present, it would handle the commercialisation of products by itself, and the rest of the markets would be taken care of through its partners. April quarter next, Aurobindo would `fairly stabilise’ its commercial supplies to Europe.
Aurobindo received four product approvals from Europe, three with the European Medicines Agency and Bevqolva (tratsuzumab) with the MHRA, and is ready to supply all these products to the European market.
Published on August 21, 2025
